Speaker
Bernd Neumaier
Summary
The combination of diagnostic imaging and targeted therapy within a single molecular framework, commonly referred to as theranostics, has become a cornerstone of precision medicine. By using diagnostic and therapeutic radiopharmaceuticals with the same molecular scaffold, these approaches enable the visualization, quantification, and treatment of pathologies with unprecedented specificity. Clinically established theranostic pairs include PSMA-targeted agents (e.g., [68Ga/177Lu]PSMA-617) for prostate cancer and somatostatin analogs (e.g., [68Ga/177Lu]DOTATATE) for neuroendocrine tumors. Beyond these established examples, novel targeting vectors and radionuclides are currently under investigation.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
Author
Bernd Neumaier
